SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

A Ninth Circuit ruling that sports-event contracts are sports bets rather than federally protected swaps is drawing attention because it could let states restrict Kalshi-style competitors, easing a key overhang for DraftKings. Traders remain divided on whether the benefit will last amid a circuit split and possible Supreme Court review, while debating prediction-market growth, sportsbook cannibalization, and margin pressure.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

Ryan Cohens reported purchase of 1 million GameStop shares is fueling renewed bullish attention, with traders linking the move to potential buybacks, rising borrow costs on related warrants, options-driven buying, and a possible short squeeze. Some participants remain skeptical, pointing to low volume, range-bound trading, and the lack of a confirmed new corporate announcement.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

FDA approval of FAYUVI, the first approved treatment for Sanfilippo syndrome Type A, is driving attention, along with the associated Priority Review Voucher and potential commercial launch. Traders are split between expecting further upside and short covering versus questioning the muted share-price reaction, limited patient population, safety/uptake risks, and Ultragenyxs cash burn.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Completion of enrollment in Helus Pharmas pivotal Phase 3 APPROACH trial for HLP003, with topline major-depression data expected in Q4 2026, is driving attention. Traders are broadly positioning for a potentially positive readout, while others cite profit-taking, funding/dilution risk and the possibility that expectations are already priced in.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcashs sharp, outsized rally and new highs are drawing attention, with traders emphasizing its privacy-focused utility, capped supply and relative strength versus Bitcoin and other major cryptocurrencies. Bullish participants point to continued buying and possible short liquidations, while skeptics warn that FOMO, overbought conditions and thin liquidity could lead to a sharp pullback.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

The Federal Reserves rate hike and signal that policy may remain tight are driving attention, with traders focused on IWMs sensitivity to higher borrowing costs and Treasury yields. The community is split between those viewing the post-Fed rebound as short covering or a relief move and those highlighting weak technicals, heavy put activity, and continued downside risk for small caps.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Uncertainty surrounding Dutch Bros planned Salad and Go location acquisition, alongside concerns about its premium valuation, consumer spending, and potential dilution, has fueled a sharp selloff toward 52-week lows despite continued store expansion and upbeat guidance. Traders are divided between bears expecting further downside as growth is repriced and bulls viewing the decline as an overreaction and accumulation opportunity.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Ultragenyxs FDA approval of FAYUVI (formerly UX111/ABO-102), a gene therapy originally developed by Abeona, is driving attention because it could generate milestone payments and royalties for ABEO. Traders are bullish on the non-operating revenue stream, while others debate the limited rare-disease market and how quickly the financial benefit will be realized.

UNI is the governance token for Uniswap, an Automated Market Marker DEX on the Ethereum blockchain. The UNI token allows token holders to participate in the governance of the protocol. Key decisions such as usage of the treasury or future upgrades can be decided through a governance vote.

UniSwap

Attention is centered on Uniswaps reported Robinhood integration and role in the platforms crypto and tokenized-asset liquidity, with traders also highlighting fee-driven UNI buybacks and burns as a potential source of value accrual. The community is broadly bullish on the partnership and recent momentum, though some traders view the move as overbought and expect consolidation or a pullback.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven is drawing attention after licensing its opakalim epilepsy program to SK Biopharmaceuticals for significant upfront cash, milestones, and royalties, reducing near-term funding pressure and shifting development costs to the partner. Traders view the deal as a balance-sheet de-risking event, while some debate whether selling commercial rights limits upside and leaves the obesity Phase 2 readout as the key near-term catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

InspireMD (NSPR) Upgraded to Buy: Here's What You Should Know

InspireMD (NSPR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

InspireMD, Inc. (NSPR) Reports Q2 Loss, Beats Revenue Estimates

InspireMD (NSPR) delivered earnings and revenue surprises of +15.00% and +7.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates

Alpha Cognition Inc. (ACOG) delivered earnings and revenue surprises of -2.56% and +41.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates

908 Devices (MASS) delivered earnings and revenue surprises of +21.43% and +5.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates

Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of +8.82% and -0.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR

NSPR's positive CGUARDIANS II data show 100% acute device success, supporting a potential FDA approval for CGuard Prime TCAR in late 2026.

InspireMD NSPR Q1 2026 Earnings Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates

InspireMD (NSPR) delivered earnings and revenue surprises of +15.79% and +25.85%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

NSPR Rallies After Hours On FDA Green Light for Key Stroke-Prevention Trial Despite Withdrawn Annual Guidance

Equity

The trial will test the safety and effectiveness of SwitchGuard when used with the company’s CGuard Prime carotid stent during transcarotid artery revascularization or TCAR procedures.


InspireMD (NYSE:NSPR) Stock Price Up 3.5% - What's Next?

InspireMD (NYSE:NSPR) Stock Price Up 3.5% - Here's What Happened...

InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Miami, FL.

InspireMD Inc

Neutral Sentiment

No more this year

One more

Two more

The Federal Reserve raised interest rates by a quarter point to a range of 3.75%-4.00% on Wednesday, its first hike since July 2023, but Fed Chair Kevin Warsh signaled the tightening cycle isn't over. How many more rate hikes do you expect by the end of 2026? Vote and explain your reasoning in the comments.

The Fed hiked rates 25bps yesterday, its first since 2023, but signaled it&#39;s not done - projections point to one or two more hikes this year. How many total hikes do you expect by year-end?

Stocktwits

The Fed hiked rates 25bps yesterday, its first since 2023, but signaled it's not done - projections point to one or two more hikes this year. How many total hikes do you expect by year-end?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.15	--	--	N/A
Q2 '26	-$0.20	-$0.17	15.00%	BEAT
Q1 '26	-$0.18	-$0.16	11.11%	BEAT
Q4 '25	-$0.19	-$0.14	27.59%	BEAT
Q3 '25	-$0.19	-$0.17	12.82%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

NSPR Earnings

Upcoming Earnings: Q3 '26

Historical Earnings